6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine: an mGluR5 antagonist; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 44557636 |
| CHEMBL ID | 2346738 |
| SCHEMBL ID | 103033 |
| MeSH ID | M000603533 |
| Synonym |
|---|
| HY-14859 |
| bdbm50431705 |
| dipraglurant [inn] |
| unii-cv8jzr21a1 |
| 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine |
| 872363-17-2 |
| dipraglurant |
| cv8jzr21a1 , |
| CS-0690 |
| 2-(4-{6-fluoroimidazo[1,2-a]pyridin-2-yl}but-1-yn-1-yl)pyridine |
| gtpl6452 |
| adx48621 |
| adx-48621 |
| CHEMBL2346738 , |
| SCHEMBL103033 |
| DTXSID90236230 |
| AKOS030526956 |
| NCGC00351745-02 |
| A916694 |
| DB12733 |
| FT-0705373 |
| 6-fluoro-2-[4-(pyridin-2-yl)-3-butynyl]imidazo[1,2-a]pyridine |
| BCP23706 |
| Q19596938 |
| 6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo[1,2-a]pyridine |
| SB16993 |
| 6-fluoro-2-(4-pyridin-2-ylbut-3-ynyl)imidazo[1,2-a]pyridine |
| 6-fluoro-2-[4-(2-pyridinyl)-3-butyn-1-yl]imidazo[1,2-a]pyridine |
| F84825 |
| MS-23750 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 10.6840 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 23.9185 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 30.1116 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 23.9185 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 23.9185 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 23.9185 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 23.9185 | AID1645842 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| Metabotropic glutamate receptor 5 | Homo sapiens (human) | IC50 | 0.0200 | AID738966 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID738966 | Negative allosteric modulation of human mGluR5 expressed in HEK293 cells assessed as calcium mobilization by FLIPR assay | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 ISSN: 1464-3405 | Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. |
| AID738946 | Antidepressant activity in ICR mouse assessed as decrease in immobility time at 50 mg/kg, po administered 1 hr before test measured for 4 mins following training for 2 mins by forced swimming test | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 ISSN: 1464-3405 | Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. |
| AID1240808 | Ex vivo occupancy at mGlu5 receptor in po dosed Sprague-Dawley rat assessed as inhibition of [3H]-M-MPEP binding measured after 1 hr post dose by autoradiography | 2015 | Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16 ISSN: 1520-4804 | Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). |
| AID1346269 | Human mGlu5 receptor (Metabotropic glutamate receptors) | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7 ISSN: 1464-3405 | Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (9.09%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3-((2-methyl-1,3-thiazol-4-yl)ethynyl)piperidine | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |||
| mavoglurant | 2015 | 2015 | 9.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |||
| 3-chloro-5-(6-(5-fluoropyridin-2-yl)pyrimidin-4-yl)benzonitrile | 2015 | 2015 | 9.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| levodopa | amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid | allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug | 2014 | 2016 | 9.0 | high | 1 | 0 | 0 | 0 | 2 | 0 | |
| mavoglurant | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congenital Zika Syndrome | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2014 | 2020 | 7.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 | |
| Dyskinesia, Drug-Induced | 0 | 2014 | 2016 | 9.0 | medium | 1 | 0 | 0 | 0 | 2 | 0 | |
| Dyskinesia, Medication-Induced | 0 | 2014 | 2016 | 9.0 | medium | 1 | 0 | 0 | 0 | 2 | 0 | |
| Dystonia | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
| Idiopathic Parkinson Disease | 0 | 2016 | 2023 | 4.5 | medium | 1 | 0 | 0 | 0 | 1 | 1 | |
| MPTP Neurotoxicity Syndrome | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Parkinson Disease | 1 | 2016 | 2023 | 4.5 | medium | 1 | 0 | 0 | 0 | 1 | 1 | |
| Zika Virus Infection | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |